Asit Parikh is Director at Phathom Pharmaceuticals, Inc. (PHAT). They have made 8 open-market trades across 1 company since 2022, most recently 2026-05-22.
CIK 0001796787
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
8 open-market purchases totalling $471K since 2022, never a sale. Across 8 scored buys the stock is up 61.4% at ninety days, and 56.2 points ahead of the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| PHAT | 148,500 | $1.0M |
Shares reported on the most recent Form 4, priced at the 2026-05-27 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 75% | 50% | 75% |
| Avg Move | +22.1% | +33.6% | +61.4% |
| Alpha | +21.4% | +34.0% | +56.2% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PHAT | BUY | 2025-05-06 | 2025-05-08 | $2.50 | $25K | +88.0% | +279.0% | +272.5% |
| PHAT | BUY | 2025-03-13 | 2025-03-17 | $4.42 | $44K | +33.3% | -15.8% | +112.0% |
| PHAT | BUY | 2024-12-13 | 2024-12-16 | $8.12 | $162K | +1.2% | -11.8% | -40.1% |
| PHAT | BUY | 2023-11-06 | 2023-11-08 | $7.81 | $59K | -11.6% | +0.6% | -15.5% |
| PHAT | BUY | 2023-04-10 | 2023-04-11 | $7.55 | $8K | +24.6% | +55.4% | +64.6% |
| PHAT | BUY | 2023-02-13 | 2023-02-14 | $7.73 | $39K | +13.3% | -20.3% | +47.1% |
| PHAT | BUY | 2023-01-12 | 2023-01-12 | $7.00 | $35K | +42.7% | +6.7% | +17.4% |
| PHAT | BUY | 2022-05-12 | 2022-05-16 | $8.00 | $100K | -14.7% | -24.6% | +32.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.